Dr. West on the Gefitinib Advanced NSCLC Trial

H. Jack West, MD
Published: Tuesday, Jul 19, 2011

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses findings from a phase III, randomized, multicenter, parallel group study (NCT00770588) that examined the efficacy of gefitinib as a maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC). The trial discovered that progression free survival was much longer in Chinese patients receiving gefitinib than those receiving placebo.
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses findings from a phase III, randomized, multicenter, parallel group study (NCT00770588) that examined the efficacy of gefitinib as a maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC). The trial discovered that progression free survival was much longer in Chinese patients receiving gefitinib than those receiving placebo.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x